CoChat
Sign Up
Cited by 455

MicroRNA-132–mediated loss of p120RasGAP activates the endothelium to facilitate pathological angiogenesis

Anand, Sudarshan, Majeti, Bharat K, Acevedo, Lisette M, Murphy, Eric A, Mukthavaram, Rajesh, Scheppke, Lea, Huang, Miller, Shields, David J +5 more·2010·Nature Medicine
DOI 10.1038/nm.2186PMC PMC3094020
Open this paper in CoChat — free account

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nm.2186

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • This potential activity of miR-338-3p is supported by its pattern of co-expression during maturation with miR-132, itself an inhibitory regulator of quiescence in other cell types.

    “This potential activity of miR-338-3p is supported by its pattern of co-expression during maturation with miR-132, itself an inhibitory regulator of quiescence in other cell types [25].”

    From MiR-338-3p regulates neuronal maturation and suppresses glioblastoma proliferation. (2017) · cites this paper as [25]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

  • Modes of resistance to anti-angiogenic therapy

    Bergers, G., & Hanahan, D. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2442 · Cited by 2,953 · cited 1× · see citing works

    “There is emerging evidence that some of the current antiangiogenic therapies, which target single pathways such as the VEGFR pathway, can lead to the development of 'evasive resistance' in tumors through the upregulation of alternative growth factor”
    Background

Flagged first, then by citations

Research works printed but not linked: 33

  1. [1]Murphy EA Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis Proc. Natl. Acad. Sci. USA 2008 105 9343 9348 18607000 PMC2453735
  2. [2]Hobson B Denekamp J Endothelial proliferation in tumours and normal tissues: continuous labelling studies Br. J. Cancer 1984 49 405 413 6201181 PMC1976759
  3. [3]Folkman J The role of angiogenesis in tumor growth Semin. Cancer Biol 1992 3 65 71 1378311
  4. [4]Fish JE Srivastava D MicroRNAs: opening a new vein in angiogenesis research Sci. Signal 2009 2 pe1 19126861 PMC2680274
  5. [5]Lindquist JN Cheresh DA Snyder EY Derivation of vasculature from embryonic stem cells Curr. Protoc. Stem Cell Biol 2010 12 1.1F.9.1 1.1F.9.6 20200855
  6. [6]Kelly MA Hirschi KK Signaling hierarchy regulating human endothelial cell development Arterioscler. Thromb. Vasc. Biol 2009 29 718 724 19213939 PMC2729243
  7. [7]Nudelman AS Neuronal activity rapidly induces transcription of the CREB-regulated microRNA-132, in vivo Hippocampus 2010 20 492 498 19557767 PMC2847008
  8. [8]Vo N A cAMP-response element binding protein–induced microRNA regulates neuronal morphogenesis Proc. Natl. Acad. Sci. USA 2005 102 16426 16431 16260724 PMC1283476
  9. [9]Mayo LD Kessler KM Pincheira R Warren RS Donner DB Vascular endothelial cell growth factor activates CRE-binding protein by signaling through the KDR receptor tyrosine kinase J. Biol. Chem 2001 276 25184 25189 11335727
  10. [10]Tan Y FGF and stress regulate CREB and ATF-1 via a pathway involving p38 MAP kinase and MAPKAP kinase-2 EMBO J 1996 15 4629 4642 8887554 PMC452194
  11. [11]Kenneth TE Kertes PJ Ranibizumab in neovascular age-related macular degeneration Clin. Interv. Aging 2006 1 451 466 18046922 PMC2699647
  12. [12]Gragoudas ES Adamis AP Cunningham ET Jr Feinsod M Guyer DR Pegaptanib for neovascular age-related macular degeneration N. Engl. J. Med 2004 351 2805 2816 15625332
  13. [13]Griffiths-Jones S Grocock RJ van Dongen S Bateman A Enright AJ miRBase: microRNA sequences, targets and gene nomenclature Nucleic Acids Res 2006 34 D140 D144 16381832 PMC1347474
  14. [14]Lewis BP Burge CB Bartel DP Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets Cell 2005 120 15 20 15652477
  15. [15]Krek A Combinatorial microRNA target predictions Nat. Genet 2005 37 495 500 15806104
  16. [16]Rehmsmeier M Steffen P Hochsmann M Giegerich R Fast and effective prediction of microRNA/target duplexes RNA 2004 10 1507 1517 15383676 PMC1370637
  17. [17]Bartel DP MicroRNAs: target recognition and regulatory functions Cell 2009 136 215 233 19167326 PMC3794896
  18. [18]Hoshino M Kawakita M Hattori S Characterization of a factor that stimulates hydrolysis of GTP bound to ras gene product p21 (GTPase-activating protein) and correlation of its activity to cell density Mol. Cell. Biol 1988 8 4169 4173 3141783 PMC365486
  19. [19]McCormick F ras GTPase activating protein: signal transmitter and signal terminator Cell 1989 56 5 8 2535967
  20. [20]Lapinski PE Generation of mice with a conditional allele of the p120 Ras GTPase-activating protein Genesis 2007 45 762 767 18064675
  21. [21]Henkemeyer M Vascular system defects and neuronal apoptosis in mice lacking ras GTPase-activating protein Nature 1995 377 695 701 7477259
  22. [22]Boon LM Mulliken JB Vikkula M RASA1: variable phenotype with capillary and arteriovenous malformations Curr. Opin. Genet. Dev 2005 15 265 269 15917201
  23. [23]Eerola I Capillary malformation-arteriovenous malformation, a new clinical and genetic disorder caused by RASA1 mutations Am. J. Hum. Genet 2003 73 1240 1249 14639529 PMC1180390
  24. [24]Hershkovitz D Bercovich D Sprecher E Lapidot M RASA1 mutations may cause hereditary capillary malformations without arteriovenous malformations Br. J. Dermatol 2008 158 1035 1040 18363760
  25. [25]Hood JD Tumor regression by targeted gene delivery to the neovasculature Science 2002 296 2404 2407 12089446
  26. [26]Fish JE miR-126 regulates angiogenic signaling and vascular integrity Dev. Cell 2008 15 272 284 18694566 PMC2604134
  27. [27]Harris TA Yamakuchi M Ferlito M Mendell JT Lowenstein CJ MicroRNA-126 regulates endothelial expression of vascular cell adhesion molecule 1 Proc. Natl. Acad. Sci. USA 2008 105 1516 1521 18227515 PMC2234176
  28. [28]Wang S The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis Dev. Cell 2008 15 261 271 18694565 PMC2685763
  29. [29]Würdinger T miR-296 regulates growth factor receptor overexpression in angiogenic endothelial cells Cancer Cell 2008 14 382 393 18977327 PMC2597164
  30. [30]Bonauer A MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice Science 2009 324 1710 1713 19460962
  31. [31]Komada M Kitamura N The Hrs/STAM complex in the downregulation of receptor tyrosine kinases J. Biochem 2005 137 1 8 15713877
  32. [32]Kulkarni SV Gish G van der Geer P Henkemeyer M Pawson T Role of p120 Ras-GAP in directed cell movement J. Cell Biol 2000 149 457 470 10769036 PMC2175152
  33. [33]Meadows KN Bryant P Vincent PA Pumiglia KM Activated Ras induces a proangiogenic phenotype in primary endothelial cells Oncogene 2004 23 192 200 14712224

Cited by

Sorted by citations

Authors
Anand, S., Majeti, B. K., Acevedo, L. M., Murphy, E. A., Mukthavaram, R., Scheppke, L., Huang, M., Shields, D. J., Lindquist, J. N., Lapinski, P. E., King, P. D., Weis, S. M., & Cheresh, D. A.
Venue
Nature Medicine
Publisher
Springer Science and Business Media LLC
Published
2010-08
Volume
16
Issue
8
Pages
909-914
ISSN
  • 1078-8956
  • 1546-170X
DOI
10.1038/nm.2186
PMC
PMC3094020
Cited by
455
References
1
Language
en
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review